. Author manuscript; available in PMC: 2017 Apr 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2015 Sep 25;22(4):617–626. doi: 10.1016/j.bbmt.2015.09.015

Table 2a.

Salient clinical features of lung injury syndromes defined under IPS

Parenchyma

Acute interstitial pneumonitis: Onset day 0-100 post-transplant. Secondary to chemotoxicity (BCNU, bleomycin, busulfan).

Acute respiratory distress syndrome (ARDS): Non-cardiogenic capillary leak syndrome with onset day 0-30 post-transplant.

Delayed pulmonary toxicity syndrome: Presents months to years after auto HSCT for breast cancer.

Vascular endothelium

Peri-engraftment respiratory distress syndrome: Present within 5-7 days of engraftment may progress to ARDS.

Diffuse alveolar hemorrhage: Progressively bloodier BAL fractions, presents within 0-100 days post-transplant.

Airway epithelium [113]

Bronchiolitis obliterans syndrome (BOS): Diminished FEV1, onset 3-24 months post-transplant. Chest radiography may be normal or show hyperinflation. Chest CT may show mosaic attenuation, air trapping, septal lines, centrilobular nodules or bronchiectasis. Histology reveals bronchiolar inflammation with luminal obstruction.

Cryptogenic organizing pneumonia (COP formerly known as Bronchiolitis obliterans organizing pneumonia or BOOP): Restrictive findings on spirometry, impaired DL_CO, onset 2-12 months post-transplant. Chest CT may show patchy airspace disease, or nodular opacities. Histology reveals intraluminal organizing fibrosis in distal airspaces with mild interstitial inflammation.